EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance

Xinyu Gou, Shi He, Bilan Wang, Lingli Zhang, Yongzhong Cheng, Xiang Gao

Advanced Drug Delivery Reviews · 2026-02 · 229 · 115755

DOI: 10.1016/j.addr.2025.115755 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-02. Verfasst von Xinyu Gou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medic…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Antineoplastic Agents, Drug Delivery Systems. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 172 Literaturangaben. Gefördert von: Sichuan University, National Natural Science Foundation of China, Sichuan Provincial Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor drug resistance is a major challenge in cancer treatment, as traditional chemotherapeutic agents and small molecule inhibitors often become ineffective in targeting tumors due to drug resistance. Proteolysis Targeting Chimeras (PROTAC) technology, as a novel protein degradation method, provides a new insight into overcoming drug resistance in tumors with the assistance of nanodelivery systems. PROTAC is able to degrade rather than merely inhibit tumor-associated proteins, thus avoiding drug resistance caused by gene mutations, protein overexpression and conformational changes, demonstrating significant advantages in overcoming tumor resistance. First, PROTAC eliminates the biological activity of the target protein by directly degrading it, thus overcoming the limitation of traditional inhibitors, which are susceptible to mutations of the structure and activity of the target protein. Second, PROTAC molecules are highly versatile and flexible, and can target proteins that are difficult to target with conventional drugs, including enzymatically inactive proteins, transcription factors and oncogenic protein complexes. In addition, PROTAC technology, with the booster of nanodelivery systems, can effectively improve solubility and bioavailability, enhance targeting and delivery efficiency while improving its stability, and can be combined with other therapeutic methods to further enhance the therapeutic effect. The versatility of PROTAC makes it a highly promising option for overcoming tumor drug resistance, and their effectiveness has been validated in a variety of cancers, including breast cancer, prostate cancer, and leukemia. In this paper, we will review the recent progress of PROTAC technology in overcoming tumor drug resistance and briefly summarize the advantages and challenges of PROTAC technology combined with nanodelivery system, hoping to provide valuable references for researchers in related fields.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmNeoplasmsAntineoplastic AgentsDrug Delivery SystemsNanoparticle Drug Delivery SystemHumansProteolysisAnimalsNanoparticles

Stichwörter der Autor:innen

CancerDrug resistanceNanodelivery systemPROTACsTargeted therapy

Substanzen

Antineoplastic AgentsNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for…
  • Department of Pharmacy, West China Second University Hospital of Sichuan University, Chengdu 610041, PR China; Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu 610041, P…

Förderung

  • Sichuan University
  • National Natural Science Foundation of China
  • Sichuan Provincial Science and Technology Support Program

Zitieren

APA

Gou, X., He, S., Wang, B., Zhang, L., Cheng, Y., & Gao, X. (2026). Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance. Advanced Drug Delivery Reviews, 229, 115755. https://doi.org/10.1016/j.addr.2025.115755

Vancouver

Gou X, He S, Wang B, Zhang L, Cheng Y, Gao X. Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance. Advanced Drug Delivery Reviews. 2026;229:115755. doi:10.1016/j.addr.2025.115755

BibTeX
@article{Gou2026,
  author = {Gou, Xinyu and He, Shi and Wang, Bilan and Zhang, Lingli and Cheng, Yongzhong and Gao, Xiang},
  title = {Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  volume = {229},
  pages = {115755},
  doi = {10.1016/j.addr.2025.115755}
}
Kostenlos starten →